Form 4: Gilead Sciences' Chief Medical Officer, Dietmar Berger, Reports Stock Transactions

Dietmar Berger, Chief Medical Officer of Gilead Sciences, reports the acquisition of restricted stock units and non-qualified stock options.

Summary

• Dietmar Berger, the Chief Medical Officer of Gilead Sciences, filed a Form 4 with the SEC.
• The filing reports transactions involving Gilead Sciences' stock.
• On March 10, 2025, Berger acquired 8,530 restricted stock units (RSUs) and 37,710 non-qualified stock options.
• The RSUs vest over four years, with 25% vesting on the first anniversary of the grant date and the balance vesting quarterly thereafter.
• The stock options also vest over four years, with 25% vesting on the first anniversary of the grant date and the balance vesting quarterly thereafter.
• The exercise price for the stock options is $117.21.
• Following the reported transactions, Berger beneficially owns 57,505 RSUs and 37,710 non-qualified stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine filing related to executive compensation. The acquisition of stock options and RSUs is generally a positive sign, indicating confidence in the company's future, but it's not overwhelmingly positive.

Positives

• The acquisition of stock options and restricted stock units by a key executive signals confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options suggest a long-term commitment by the executive to the company's success.

Industry Context

Executive stock transactions are common in the pharmaceutical industry and are often used to align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants and RSU awards are standard compensation practices for executives in publicly traded companies, including those in the pharmaceutical sector like Pfizer (PFE), Merck (MRK), and Johnson & Johnson (JNJ).
• The vesting schedules (25% on the first anniversary, then quarterly) are typical for these types of equity grants.
• The size of the grant should be compared to similar grants made to executives at comparable companies to determine if it is above or below industry averages.

Stakeholder Impact

• The vesting of stock options and RSUs aligns the executive's interests with those of shareholders, potentially driving long-term value creation.

Key Dates